Retrospective study shows that early administration of convalescent plasma in hospitalized COVID-19 patients may have a positive effect on disease progression.
作者信息
Birschmann Ingvild, von Bargen Katharina, Teune Michelle, Flottmann Christian, Knüttgen Franziska, Knabbe Cornelius
机构信息
Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum Institut für Laboratoriums- und Transfusionsmedizin Bad Oeynhausen Germany.
Lukas Krankenhaus Bünde Medizinische Klinik II - Innere Medizin und Kardiologie Bünde Germany.
出版信息
Health Sci Rep. 2022 Aug 9;5(5):e714. doi: 10.1002/hsr2.714. eCollection 2022 Sep.
Abstract
摘要
相似文献
1
Retrospective study shows that early administration of convalescent plasma in hospitalized COVID-19 patients may have a positive effect on disease progression.回顾性研究表明，对住院的新冠肺炎患者早期给予康复期血浆可能对疾病进展有积极影响。
Health Sci Rep. 2022 Aug 9;5(5):e714. doi: 10.1002/hsr2.714. eCollection 2022 Sep.
2
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体（RES-Q-HR）：一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
3
Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.康复期或对照血浆输注治疗早期门诊 COVID-19 后，地方性人冠状病毒抗体水平保持不变。
mBio. 2023 Feb 28;14(1):e0328722. doi: 10.1128/mbio.03287-22. Epub 2023 Jan 10.
4
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.一项随机、多中心、开放性 II 期概念验证临床试验，旨在研究恢复期血浆联合 COVID-19 住院患者标准治疗的临床疗效和安全性：捐赠抗体对抗新型冠状病毒（DAWn-Plasma）试验。
Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0.
5
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.评估人抗 SARS-CoV-2 恢复期血浆在 COVID-19 重症成人中的疗效和安全性：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.
6
Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State.在资源有限的情况下，使用两单位恢复期血浆治疗 COVID-19 患者。
Lab Med. 2022 Nov 3;53(6):623-628. doi: 10.1093/labmed/lmac055.
7
Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.利用雅培 SARS-CoV-2 IgG II 定量检测分析试剂盒鉴定针对野生型和变异型 SARS-CoV-2 病毒的高滴度抗 SARS-CoV-2 中和血浆。
Microbiol Spectr. 2022 Oct 26;10(5):e0281122. doi: 10.1128/spectrum.02811-22. Epub 2022 Sep 20.
8
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.随机临床试验评估 COVID-19 住院患者使用恢复期血浆的安全性和疗效（PERUCONPLASMA）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6.
9
Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.SARS-CoV-2 血清学检测在使用 FDA 阈值鉴定高滴度 COVID-19 恢复期血浆中的相关性有限。
Microbiol Spectr. 2022 Aug 31;10(4):e0115422. doi: 10.1128/spectrum.01154-22. Epub 2022 Jul 5.
10
Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.在一大群2019冠状病毒病（COVID-19）患者中，早期输注含有高滴度抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白IgG的康复期血浆可显著降低死亡率。
Am J Pathol. 2021 Jan;191(1):90-107. doi: 10.1016/j.ajpath.2020.10.008. Epub 2020 Nov 4.
本文引用的文献
1
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.恢复期血浆疗法与血液系统恶性肿瘤合并 COVID-19 患者生存情况的关联
JAMA Oncol. 2021 Jun 17;7(8):1167-75. doi: 10.1001/jamaoncol.2021.1799.
2
Use of convalescent plasma in COVID-19 patients with immunosuppression.COVID-19 免疫抑制患者使用恢复期血浆。
Transfusion. 2021 Aug;61(8):2503-2511. doi: 10.1111/trf.16525. Epub 2021 Jun 1.
3
Convalescent plasma treatment of critically ill intensive care COVID-19 patients.恢复期血浆治疗危重症 COVID-19 患者的 ICU 治疗。
Transfusion. 2021 May;61(5):1394-1403. doi: 10.1111/trf.16392. Epub 2021 Apr 8.
4
Severe covid-19 pneumonia: pathogenesis and clinical management.严重 COVID-19 肺炎：发病机制与临床管理。
BMJ. 2021 Mar 10;372:n436. doi: 10.1136/bmj.n436.
5
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.恢复期血浆抗体水平与新冠死亡风险。
N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13.
6
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.早期高滴度血浆疗法预防老年人重症 COVID-19。
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
7
8
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.ACE2 受体的作用以及从恢复期血浆疗法到药物再利用治疗 COVID-19 的治疗选择全景。
Mol Cell Biochem. 2021 Feb;476(2):553-574. doi: 10.1007/s11010-020-03924-2. Epub 2020 Oct 7.
9
Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.使用恢复期血浆治疗 2019 年冠状病毒病患者显示出死亡率显著降低的信号。
Am J Pathol. 2020 Nov;190(11):2290-2303. doi: 10.1016/j.ajpath.2020.08.001. Epub 2020 Aug 11.
10
Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.康复期血浆治疗新型冠状病毒肺炎感染的临床疗效：一项多中心临床研究的结果
Transfus Apher Sci. 2020 Oct;59(5):102875. doi: 10.1016/j.transci.2020.102875. Epub 2020 Jul 15.
Zotero 插件